Technical Analysis for FULC - Fulcrum Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Volume Surge | Other | 1.77% | |
| Inside Day | Range Contraction | 1.77% | |
| Wide Bands | Range Expansion | 1.77% | |
| Oversold Stochastic | Weakness | 1.77% | |
| Slingshot Bearish | Bearish Swing Setup | 0.48% | |
| Stochastic Buy Signal | Bullish | 0.48% | |
| Wide Bands | Range Expansion | 0.48% | |
| Gapped Up | Strength | 0.48% |
| Alert | Time |
|---|---|
| Up 2% | about 5 hours ago |
| 60 Minute Opening Range Breakout | about 6 hours ago |
| 60 Minute Opening Range Breakdown | about 10 hours ago |
| Down 3% | about 10 hours ago |
| Fell Below Previous Day's Low | about 10 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/01/2024
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Disability Disorders Dystrophy Muscular Dystrophy Progressive Hemoglobin Infancy Sickle Cell Disease Thalassemia Facioscapulohumeral Muscular Dystrophy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Disease Disability Disorders Dystrophy Muscular Dystrophy Progressive Hemoglobin Infancy Sickle Cell Disease Thalassemia Facioscapulohumeral Muscular Dystrophy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.7 |
| 52 Week Low | 3.14 |
| Average Volume | 791,388 |
| 200-Day Moving Average | 6.80 |
| 50-Day Moving Average | 7.39 |
| 20-Day Moving Average | 7.20 |
| 10-Day Moving Average | 6.38 |
| Average True Range | 0.47 |
| RSI (14) | 37.89 |
| ADX | 23.33 |
| +DI | 16.18 |
| -DI | 30.10 |
| Chandelier Exit (Long, 3 ATRs) | 7.29 |
| Chandelier Exit (Short, 3 ATRs) | 7.08 |
| Upper Bollinger Bands | 8.96 |
| Lower Bollinger Band | 5.43 |
| Percent B (%b) | 0.25 |
| BandWidth | 49.01 |
| MACD Line | -0.44 |
| MACD Signal Line | -0.34 |
| MACD Histogram | -0.0999 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.95 | ||||
| Resistance 3 (R3) | 6.89 | 6.62 | 6.84 | ||
| Resistance 2 (R2) | 6.62 | 6.45 | 6.65 | 6.81 | |
| Resistance 1 (R1) | 6.46 | 6.35 | 6.54 | 6.52 | 6.77 |
| Pivot Point | 6.19 | 6.19 | 6.23 | 6.22 | 6.19 |
| Support 1 (S1) | 6.04 | 6.03 | 6.12 | 6.10 | 5.85 |
| Support 2 (S2) | 5.77 | 5.93 | 5.80 | 5.81 | |
| Support 3 (S3) | 5.61 | 5.77 | 5.78 | ||
| Support 4 (S4) | 5.67 |
